Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Nancy Lane, ACR 2022: A phase 2 study of lorecivivint injections for the treatment of knee osteoarthritis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 30th 2022

Lorecivivint is an intra-articular CLK/DYRK inhibitor recently studied in a phase 2 clinical trial for the treatment of knee osteoarthritis (NCT03727022). In this touchIMMUNOLOGY interview, we caught up with Dr. Nancy Lane (University of California Davis, Sacramento, CA, USA) to discuss the aims, design, eligibility criteria and efficacy and safety findings of the study.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract ‘A Phase 2, 104-Week Study of Repeat Lorecivivint Injections Evaluating Safety, Efficacy, and Bone Health Utilizing Quantitative Computed Tomography (qCT) in Knee Osteoarthritis (OA-06).’ (Abstract number: 1894) was presented at the ACR Convergence, November 10–14, 2022.

Questions

  1. What are the unmet needs in the treatment of knee osteoarthritis? (0:36)
  2. What is lorecivivint and what is the rationale for its use in this indication? (1:03)
  3. What were the aims, design and eligibility criteria of the study? (2:46)
  4. What were the efficacy and safety findings of the study? (3:39)
  5. What were the limitations of the study and what further studies are planned? (4:32)

Disclosures: Nancy Lane discloses consulting for Biosplice, receiving grant/research support from NIA, serving on advisory boards for Xalud and Genescense, and participating in speaker’s bureaus with Amgen.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ACR Convergence 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup